Cipher Pharmaceuticals Inc
TSX:CPH

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
TSX:CPH
Watchlist
Price: 14.74 CAD 0.55%
Market Cap: 377.2m CAD
Have any thoughts about
Cipher Pharmaceuticals Inc?
Write Note

Cipher Pharmaceuticals Inc
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cipher Pharmaceuticals Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Cipher Pharmaceuticals Inc
TSX:CPH
EPS (Diluted)
$0
CAGR 3-Years
49%
CAGR 5-Years
N/A
CAGR 10-Years
-7%
Bausch Health Companies Inc
TSX:BHC
EPS (Diluted)
$0
CAGR 3-Years
47%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
EPS (Diluted)
CA$0
CAGR 3-Years
36%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
EPS (Diluted)
$0
CAGR 3-Years
50%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
EPS (Diluted)
-$1
CAGR 3-Years
27%
CAGR 5-Years
16%
CAGR 10-Years
0%
C
Curaleaf Holdings Inc
CNSX:CURA
EPS (Diluted)
$0
CAGR 3-Years
-101%
CAGR 5-Years
-59%
CAGR 10-Years
N/A
No Stocks Found

Cipher Pharmaceuticals Inc
Glance View

Market Cap
377.2m CAD
Industry
Pharmaceuticals

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

CPH Intrinsic Value
11.79 CAD
Overvaluation 20%
Intrinsic Value
Price

See Also

What is Cipher Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
0.6 USD

Based on the financial report for Sep 30, 2024, Cipher Pharmaceuticals Inc's EPS (Diluted) amounts to 0.6 USD.

What is Cipher Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-7%

Over the last year, the EPS (Diluted) growth was -51%. The average annual EPS (Diluted) growth rates for Cipher Pharmaceuticals Inc have been 49% over the past three years , and -7% over the past ten years .

Back to Top